Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F15%3A10312773" target="_blank" >RIV/00216208:11150/15:10312773 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/15:10312773 RIV/00179906:_____/15:10312773

Výsledek na webu

<a href="http://www.clinexprheumatol.org/abstract.asp?a=8311" target="_blank" >http://www.clinexprheumatol.org/abstract.asp?a=8311</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis

Popis výsledku v původním jazyce

Leflunomide (LEF) is a disease-modifying anti-rheumatic drug used for treating rheumatoid arthritis (RA). More than 50% of patients are withdrawn from LEF treatment within one year, mainly due to AEs. Importantly, it is not possible to predict which patients will respond to LEF therapy nor if adverse outcome occurs. Pharmacogenetic studies indicate an impact of single nucleotid polymorphisms (SNPs) on the variability in LEF serum levels with potential relevance to effectiveness and tolerability in individual RA patients. In vitro studies have demonstrated that cytochromes P450 (CYPs), mainly CYP1A2, CYP2C19, and CYP3A4, are involved in LEF metabolite activation. It was shown that CYP1A2* IF allele may be associated with LEF toxicity in patients with RA. In case of dihydroorotate dehydrogenase (DHODH) gene SNP (rs3213422, 19C>A), it was shown that C allele may be associated with LEF toxicity and therapeutic effect. finally, oestrogen receptor genes SNPs in females may be associated with

Název v anglickém jazyce

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis

Popis výsledku anglicky

Leflunomide (LEF) is a disease-modifying anti-rheumatic drug used for treating rheumatoid arthritis (RA). More than 50% of patients are withdrawn from LEF treatment within one year, mainly due to AEs. Importantly, it is not possible to predict which patients will respond to LEF therapy nor if adverse outcome occurs. Pharmacogenetic studies indicate an impact of single nucleotid polymorphisms (SNPs) on the variability in LEF serum levels with potential relevance to effectiveness and tolerability in individual RA patients. In vitro studies have demonstrated that cytochromes P450 (CYPs), mainly CYP1A2, CYP2C19, and CYP3A4, are involved in LEF metabolite activation. It was shown that CYP1A2* IF allele may be associated with LEF toxicity in patients with RA. In case of dihydroorotate dehydrogenase (DHODH) gene SNP (rs3213422, 19C>A), it was shown that C allele may be associated with LEF toxicity and therapeutic effect. finally, oestrogen receptor genes SNPs in females may be associated with

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical and Experimental Rheumatology

ISSN

0392-856X

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

7

Strana od-do

426-432

Kód UT WoS článku

000357769900021

EID výsledku v databázi Scopus

2-s2.0-84939549194